➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Merck
Johnson and Johnson
Moodys

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TERIPARATIDE

« Back to Dashboard

All Clinical Trials for Teriparatide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000400 Alendronate and/or Parathyroid Hormone for Osteoporosis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-08-01 This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00000400 Alendronate and/or Parathyroid Hormone for Osteoporosis Completed Massachusetts General Hospital Phase 2 1999-08-01 This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00005006 Parathyroid Hormone (PTH) With Alendronate for Osteoporosis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1987-09-01 This study investigates the effectiveness of parathyroid hormone (PTH) in combination with alendronate, a standard treatment for osteoporosis that blocks or reduces bone loss. We are using alendronate because it may help protect patients against any possible harmful effects of PTH in cortical bone such as the long bones or hip. We are testing two different treatment schedules of PTH-one in which we give PTH daily and one in which we give PTH for 3 out of every 6 months in a cyclical fashion. The entire study is 21 months long; the active treatment period is 18 months with a 6-month followup period. The main effects we will look for in this study are changes in body chemicals that are signs of bone formation or bone breakdown, and changes in bone density throughout the skeleton. We will randomly assign all study participants, who are women aged 50 and over, to either stay on alendronate alone, receive daily continuous PTH plus alendronate, or receive daily PTH for 3 months out of every 6 for a total of three separate 3-month cycles of PTH plus daily alendronate.
NCT00005006 Parathyroid Hormone (PTH) With Alendronate for Osteoporosis Completed Helen Hayes Hospital Phase 2 1987-09-01 This study investigates the effectiveness of parathyroid hormone (PTH) in combination with alendronate, a standard treatment for osteoporosis that blocks or reduces bone loss. We are using alendronate because it may help protect patients against any possible harmful effects of PTH in cortical bone such as the long bones or hip. We are testing two different treatment schedules of PTH-one in which we give PTH daily and one in which we give PTH for 3 out of every 6 months in a cyclical fashion. The entire study is 21 months long; the active treatment period is 18 months with a 6-month followup period. The main effects we will look for in this study are changes in body chemicals that are signs of bone formation or bone breakdown, and changes in bone density throughout the skeleton. We will randomly assign all study participants, who are women aged 50 and over, to either stay on alendronate alone, receive daily continuous PTH plus alendronate, or receive daily PTH for 3 months out of every 6 for a total of three separate 3-month cycles of PTH plus daily alendronate.
NCT00035256 Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Completed Eli Lilly and Company Phase 4 2001-10-01 The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed with raloxifene HCl. All qualifying study participants will receive the study drug followed by treatment with raloxifene HCl or placebo. All study participants will receive raloxifene HCl in the third phase of the study.
NCT00046137 Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis Completed Eli Lilly and Company Phase 3 1969-12-31 The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporosis more than teriparatide alone.
NCT00051558 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis Completed Eli Lilly and Company Phase 3 2002-11-01 Osteoporosis is a condition in which the amount of bone is reduced, the bones are weak, and there is an increased risk for fractures. Glucocorticoids (such as prednisone) are prescribed to treat a large number of conditions such as arthritis and asthma. When taken for several months or longer, glucocorticoids can cause bone loss and lead to a form of osteoporosis called "glucocorticoid-induced osteoporosis." This study compared the effects of teriparatide, the study drug, with alendronate, an approved drug for treating glucocorticoid-induced osteoporosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Teriparatide

Condition Name

Condition Name for Teriparatide
Intervention Trials
Osteoporosis 65
Osteoporosis, Postmenopausal 13
Postmenopausal Osteoporosis 11
Osteoporosis, Post-Menopausal 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Teriparatide
Intervention Trials
Osteoporosis 99
Osteoporosis, Postmenopausal 32
Fractures, Bone 18
Hip Fractures 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Teriparatide

Trials by Country

Trials by Country for Teriparatide
Location Trials
United States 237
Canada 38
Denmark 14
Germany 12
Spain 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Teriparatide
Location Trials
New York 19
Georgia 12
Nebraska 12
California 12
Massachusetts 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Teriparatide

Clinical Trial Phase

Clinical Trial Phase for Teriparatide
Clinical Trial Phase Trials
Phase 4 45
Phase 3 30
Phase 2/Phase 3 3
[disabled in preview] 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Teriparatide
Clinical Trial Phase Trials
Completed 74
Recruiting 16
Not yet recruiting 15
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Teriparatide

Sponsor Name

Sponsor Name for Teriparatide
Sponsor Trials
Eli Lilly and Company 50
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 8
Massachusetts General Hospital 7
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Teriparatide
Sponsor Trials
Other 127
Industry 81
NIH 18
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Harvard Business School
Merck
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.